Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050053/S069

Infuse Bone Graft

Medtronic, Inc. · Decision date Jul 28, 2026

FDA DECISIONP050053/S069

What did the FDA approve?

FDA records P050053/S069 as a supplement to PMA P050053, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 28, 2026.

FDA approval order statement

Approval to offer an alternatively configured Infuse Bone Graft kit in which the sterile water for injection (sWFI) vials, syringes, and needles have been removed from the kit, as well as minor labeling changes associated with this alternative kit configuration.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Dental
Decision date
Jul 28, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P050053/S069
Regulatory pathway
PMA supplement
Product code
NPZ
Decision code
APPR
Decision date
Jul 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Bone grafting material, dental, with biologic component.

Product code
NPZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050053/S069 received

    Application receipt date recorded by FDA.

  2. P050053/S069 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P050053. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050053

Product / regulatory recordCompanyPathwayDecision dateSource
INFUSE Bone GraftP050053/S067
Medtronic, Inc.PMA supplementFeb 24, 2026FDA
INFUSE Bone GraftP050053/S068
Medtronic, Inc.PMA supplementMar 19, 2026FDA
INFUSE BONE GRAFTP050053/S066
Medtronic, Inc.PMA supplementAug 26, 2026FDA

Explore the linked device profile

Other records with product code NPZ

Product / regulatory recordCompanyPathwayDecision dateSource
Lynch Biologics, LLCPMA supplementAug 3, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
1800 Pyramid Pl., Memphis, TN, 38132

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records